$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

$auph Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023005341 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$34.41M	$28.44M	$134.0M
YoY Change	59.12%	21.5%	193.89%
Cost Of Revenue	$421.0K	$1.362M	$5.664M
YoY Change	64.45%	183.16%	419.16%
Gross Profit	$33.99M	$27.07M	$128.4M
YoY Change	59.05%	18.1%	188.37%
Gross Profit Margin	98.78%	95.21%	95.77%
Selling, General & Admin	$50.12M	$47.47M	$196.4M
YoY Change	10.9%	7.3%	14.59%
% of Gross Profit	147.48%	175.35%	153.0%
Research & Development	$13.16M	$9.870M	$45.00M
YoY Change	4.26%	-11.47%	-11.94%
% of Gross Profit	38.71%	36.46%	35.06%
Depreciation & Amortization	$623.0K	$219.0K	$2.706M
YoY Change	-9.32%	-68.17%	308.14%
% of Gross Profit	1.83%	0.81%	2.11%
Operating Expenses	$13.16M	$56.54M	$241.4M
YoY Change	4.26%	0.76%	8.49%
Operating Profit	-$29.58M	-$28.10M	-$111.5M
YoY Change	-21.9%	-14.08%	-38.32%
Interest Expense	$3.814M	$2.909M	$5.118M
YoY Change	1355.73%	2568.81%	867.49%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$25.77M	-$25.19M	-$106.4M
YoY Change	-31.5%	-22.72%	-40.98%
Income Tax	$436.0K	$855.0K	$1.828M
% Of Pretax Income
Net Earnings	-$26.21M	-$26.05M	-$108.2M
YoY Change	-30.36%	-21.84%	-40.22%
Net Earnings / Revenue	-76.16%	-91.6%	-80.71%
Basic Earnings Per Share	-$0.18	-$0.18	-$0.76
Diluted Earnings Per Share	-$0.18	-$0.18	-$0.76
COMMON SHARES
Basic Shares Outstanding	142.6M shares	142.1M shares	141.9M shares
Diluted Shares Outstanding	142.6M shares		141.9M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$361.5M	$389.4M	$389.4M
YoY Change	-13.66%	-16.45%	-16.45%
Cash & Equivalents	$88.33M	$94.09M	$94.17M
Short-Term Investments	$272.5M	$295.2M	$295.2M
Other Short-Term Assets	$1.227M	$1.334M	$14.91M
YoY Change	-69.06%	67.59%	19.25%
Inventory	$31.75M	$24.75M	$24.75M
Prepaid Expenses	$10.10M	$13.58M
Receivables	$19.05M	$13.48M	$13.48M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$423.6M	$442.5M	$442.5M
YoY Change	-11.3%	-13.79%	-13.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.842M	$3.650M	$8.557M
YoY Change	-11.31%	-17.38%	-12.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.36M	$13.34M	$13.34M
YoY Change	12.83%	12.68%	12.68%
Total Long-Term Assets	$28.11M	$28.32M	$28.32M
YoY Change	-4.0%	-5.73%	-5.73%
TOTAL ASSETS
Total Short-Term Assets	$423.6M	$442.5M	$442.5M
Total Long-Term Assets	$28.11M	$28.32M	$28.32M
Total Assets	$451.8M	$470.9M	$470.9M
YoY Change	-10.88%	-13.34%	-13.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.680M	$11.71M	$11.71M
YoY Change	12.64%	201.8%	201.8%
Accrued Expenses	$32.17M	$28.59M	$28.59M
YoY Change	6.99%	-11.0%	-11.0%
Deferred Revenue	$3.157M	$3.148M
YoY Change		1556.84%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$42.05M	$46.11M	$46.11M
YoY Change	24.26%	13.44%	13.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.30M	$12.20M	$19.32M
YoY Change	-29.31%	-23.75%	-18.25%
Total Long-Term Liabilities	$12.30M	$12.20M	$19.32M
YoY Change	-29.31%	-23.75%	-18.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.05M	$46.11M	$46.11M
Total Long-Term Liabilities	$12.30M	$12.20M	$19.32M
Total Liabilities	$61.35M	$65.43M	$65.43M
YoY Change	4.38%	1.79%	1.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$890.5M	-$864.3M
YoY Change	12.19%	14.31%
Common Stock	$88.89M	$85.49M
YoY Change	37.41%	44.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$390.4M	$405.4M	$405.4M
YoY Change
Total Liabilities & Shareholders Equity	$451.8M	$470.9M	$470.9M
YoY Change	-10.88%	-13.34%	-13.34%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$26.21M	-$26.05M	-$108.2M
YoY Change	-30.36%	-21.84%	-40.22%
Depreciation, Depletion And Amortization	$623.0K	$219.0K	$2.706M
YoY Change	-9.32%	-68.17%	308.14%
Cash From Operating Activities	-$31.67M	$10.45M	-$79.53M
YoY Change	-32.25%	-140.31%	-49.57%
INVESTING ACTIVITIES
Capital Expenditures	$509.0K	$134.0K	$292.0K
YoY Change	-744.3%	-482.86%	-119.45%
Acquisitions
YoY Change
Other Investing Activities	$25.37M	-$2.884M	-$60.34M
YoY Change	-147.92%	-47.1%	-41.06%
Cash From Investing Activities	$24.86M	-$3.018M	-$60.63M
YoY Change	-146.89%	-45.0%	-41.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.639M	688.0K	$2.433M
YoY Change	304.69%	-99.67%	-98.9%
NET CHANGE
Cash From Operating Activities	-$31.67M	10.45M	-$79.53M
Cash From Investing Activities	$24.86M	-3.018M	-$60.63M
Cash From Financing Activities	$1.639M	688.0K	$2.433M
Net Change In Cash	-$5.171M	8.120M	-$137.7M
YoY Change	-94.8%	-95.34%	240.49%
FREE CASH FLOW
Cash From Operating Activities	-$31.67M	$10.45M	-$79.53M
Capital Expenditures	$509.0K	$134.0K	$292.0K
Free Cash Flow	-$32.18M	$10.32M	-$79.82M
YoY Change	-31.05%	-139.85%	-48.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001600620
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36421
CY2022	dei	Entity Registrant Name EntityRegistrantName	Aurinia Pharmaceuticals Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	#1203-4464 Markham Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Victoria
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V8Z 7X8
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1231763
CY2022	dei	City Area Code CityAreaCode	(250)
CY2022	dei	Local Phone Number LocalPhoneNumber	708-4272
CY2022	dei	Security12b Title Security12bTitle	Common shares, no par value
CY2022	dei	Trading Symbol TradingSymbol	AUPH
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1420000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	142576689	shares
CY2022	dei	Auditor Firm AuditorFirmId	271
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022	dei	Auditor Location AuditorLocation	Oakville, Canada
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94172000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	usd
CY2022Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	295218000	usd
CY2021Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	234178000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	13483000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15414000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	24752000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	19326000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13580000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11710000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1334000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	796000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	442539000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	513324000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13339000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11838000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3650000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4418000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6425000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8404000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4907000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5383000	usd
CY2022Q4	us-gaap	Assets Assets	470860000	usd
CY2021Q4	us-gaap	Assets Assets	543367000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	39990000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34947000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3148000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	190000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2033000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4450000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	936000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1059000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46107000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40646000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12166000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15950000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7152000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7680000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	65425000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	64276000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142268000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142268000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141600000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141600000	shares
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1185309000	usd
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1177051000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	85489000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	59014000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1061000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-852000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-864302000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-756122000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	405435000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	479091000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	470860000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	543367000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	134030000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45605000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50118000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5664000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1091000	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	196371000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	173536000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	97272000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44988000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51139000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50327000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1523000	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-574000	usd
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-6809000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	245500000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	226340000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	154408000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-111470000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-180735000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-104290000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5118000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	529000	usd
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1516000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-106352000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-180206000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102774000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1828000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	760000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108180000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-209000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-47000	usd
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108389000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-181013000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102680000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.40
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.40
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141915000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141915000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129369000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129369000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118473000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118473000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	298600000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	187732000	usd
CY2020	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6643000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17454000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	196740000	usd
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	365000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23421000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	585000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31243000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-47000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	479091000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	521000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1912000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32300000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-209000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108180000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	405435000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108180000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2706000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2761000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1371000	usd
CY2022	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	0	usd
CY2021	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	10000000	usd
CY2020	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	32300000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	31243000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	17454000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	3646000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	245000	usd
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3184000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-658000	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-9477000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1927000	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	15415000	usd
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	650000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9072000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5644000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13927000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2404000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5335000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2559000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	839000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-247000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2022	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-476000	usd
CY2021	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-106000	usd
CY2020	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	5489000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	699000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4076000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13620000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3048000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-652000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	332000	usd
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	8407000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-79529000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-157692000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69858000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	464316000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	354427000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	52108000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	523993000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	438958000	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	202951000	usd
CY2022	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	663000	usd
CY2021	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	11838000	usd
CY2020	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	0	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	6000000	usd
CY2020	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	292000	usd
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	303000	usd
CY2020	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	5668000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	0	usd
CY2021	us-gaap	Payments For Software PaymentsForSoftware	1198000	usd
CY2020	us-gaap	Payments For Software PaymentsForSoftware	1675000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60632000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-103870000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-158186000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	196740000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	187732000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2433000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24007000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6642000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	365000	usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2433000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	221112000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	194375000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-137728000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40450000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33669000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94172000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	usd
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2344000	usd
CY2021	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	749000	usd
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1884000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1979000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	257000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	261000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94088000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231643000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272350000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	84000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	257000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94172000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure </span>of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from those estimates.
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	100000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	300000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of credit risk: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and restricted cash, short term investments and accounts receivable, net. The Company attempts to minimize the risks related to cash and cash equivalents and restricted cash and investments by investing in a range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as high quality corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, Swiss Franc and Great British Pound will </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses, including commercial and clinical trial costs are also denominated in U.S. dollars, which mitigates the risk of material foreign exchange fluctuations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the Otsuka Territories. Revenues from the Company's two main customers in the U.S. accounted for approximately 45% and 35%, respectively, of the Company's total revenues for the year ended December 31, 2022. The two main customers accounted for 100% of the Company’s accounts receivable, net balance as of December 31, 2022. Otsuka, the Company's collaboration partner for sales outside the U.S. accounted for approximately 20% of the Company's total revenue for the year ended December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. customers, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2023. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to our customers or receivables.</span></div>
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	13500000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15400000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94200000	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	256000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45000000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51100000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50300000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	16300000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	15400000	usd
CY2020	us-gaap	Advertising Expense AdvertisingExpense	10000000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	196400000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	173500000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	97300000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	389390000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	466078000	usd
CY2022Q4	auph	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Short Term Investments CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments	389400000	usd
CY2021Q4	auph	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Short Term Investments CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments	466100000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	295500000	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	215000000	usd
CY2021Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent	19200000	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	389646000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	389390000	usd
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	446897000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	usd
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	47000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	446850000	usd
CY2021Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent	19228000	usd
CY2021Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent	19228000	usd
CY2021Q4	auph	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Short Term Investments CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments	466078000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	1100000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	100000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-300000	usd
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-47000	usd
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-47000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3900000	usd
CY2022Q4	auph	Inventory Deposits InventoryDeposits	5500000	usd
CY2021Q4	auph	Inventory Deposits InventoryDeposits	3900000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2217000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2217000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	21059000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12566000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1476000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4543000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	24752000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	19326000	usd
CY2022Q4	auph	Prepaid Assets Current PrepaidAssetsCurrent	5451000	usd
CY2021Q4	auph	Prepaid Assets Current PrepaidAssetsCurrent	5316000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	6330000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	4762000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1799000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1632000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13580000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11710000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5105000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5254000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1455000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	836000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3650000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4418000	usd
CY2022	us-gaap	Depreciation Depreciation	629000	usd
CY2021	us-gaap	Depreciation Depreciation	663000	usd
CY2020	us-gaap	Depreciation Depreciation	82000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19568000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13143000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6425000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19470000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11066000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8404000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	5600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	5600000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20157000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18500000	usd
CY2022Q4	auph	Commercial Related Accruals Current CommercialRelatedAccrualsCurrent	8620000	usd
CY2021Q4	auph	Commercial Related Accruals Current CommercialRelatedAccrualsCurrent	5055000	usd
CY2022Q4	auph	Accrued Research Current AccruedResearchCurrent	5350000	usd
CY2021Q4	auph	Accrued Research Current AccruedResearchCurrent	4383000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3087000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3879000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2151000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2316000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	625000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	814000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	39990000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34947000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	134030000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45605000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50118000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	8557000	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	9801000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-112359000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-180374000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61024000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	6007000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	168000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-41750000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-106352000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-180206000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102774000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1828000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	760000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-94000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1828000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	760000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-94000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1828000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	760000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.267
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1200000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.267
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.024
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.061
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.081
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.045
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.045
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.218
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.260
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.017
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	141020000	usd
CY2021Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	21000000	chf
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	120274000	usd
CY2022Q4	auph	Deferred Tax Assets Expense Share Issue Costs DeferredTaxAssetsExpenseShareIssueCosts	4209000	usd
CY2021Q4	auph	Deferred Tax Assets Expense Share Issue Costs DeferredTaxAssetsExpenseShareIssueCosts	6016000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1400000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1086000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7462000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6059000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1663000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3391000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3980000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2887000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2653000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4287000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3473000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	166319000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	143541000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	164514000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	141348000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1805000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2193000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1128000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1356000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	677000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	837000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1805000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2193000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	23200000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	518100000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12200000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16000000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1160000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	646000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	267000	usd
CY2022	us-gaap	Short Term Lease Payments ShortTermLeasePayments	57000	usd
CY2021	us-gaap	Short Term Lease Payments ShortTermLeasePayments	419000	usd
CY2020	us-gaap	Short Term Lease Payments ShortTermLeasePayments	5804000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	982000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1113000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1141000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1169000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1198000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4533000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10136000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2048000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8088000	usd
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11800000	usd
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10500000	chf
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	85000000	usd
CY2022Q4	auph	Lessee Operating Lease Lease Not Yet Commenced Payments Prior To Commencement Of Lease LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease	900000	usd
CY2022Q4	auph	Lessee Operating Lease Lease Not Yet Commenced Liability To Be Paid LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid	100000	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142300000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142300000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141600000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141600000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126700000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126700000	shares
CY2020	auph	Warrants Exercised During Period Shares WarrantsExercisedDuringPeriodShares	500	shares
CY2021	auph	Warrants Exercised During Period Shares WarrantsExercisedDuringPeriodShares	1700000	shares
CY2021	auph	Warrants Exercised During Period Shares WarrantsExercisedDuringPeriodShares	1700000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12074000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M9D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	121141000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3913000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11140
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	77000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6550
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2615000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14320
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13295000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.09
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M26D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	21000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8345000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.94
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12884000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.98
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.34
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.58
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	49200000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	24900000	usd
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	14900000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	900000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	50300000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13100000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.70
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.52
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0206
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0046
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0055
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	347000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	13.33
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2374000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.16
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	305000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	14.17
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	436000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	12.21
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1980000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	10.84
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32300000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31200000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17500000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32300000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31243000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17454000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	22780000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108180000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141915000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141915000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129369000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129369000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118473000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118473000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.40
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.40
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15275000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12329000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15737000	shares
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21625000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28191000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55779000	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28435000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	59507000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	64180000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	65278000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	56535000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-37882000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35989000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9499000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-28100000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-35515000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-8989000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-26046000	usd
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	914000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6620000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14667000	usd
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23404000	usd
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	51457000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	53754000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	65020000	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	56109000	usd
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50543000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-47134000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-50353000	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-32705000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-47010000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-50255000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-33322000	usd
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25

Files In Submission

Name	View Source	Status
auph-20221231_pre.xml	Edgar Link	unprocessable
auph-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
auph-20221231_lab.xml	Edgar Link	unprocessable
0001628280-23-005341-index-headers.html	Edgar Link	pending
0001628280-23-005341-index.html	Edgar Link	pending
0001628280-23-005341.txt	Edgar Link	pending
0001628280-23-005341-xbrl.zip	Edgar Link	pending
a2022consentpwc.jpg	Edgar Link	pending
auph-20221231.htm	Edgar Link	pending
auph-20221231.xsd	Edgar Link	pending
auph-20221231_g1.jpg	Edgar Link	pending
auph-20221231_g2.jpg	Edgar Link	pending
auph-20221231_g3.jpg	Edgar Link	pending
auph-20221231_g4.jpg	Edgar Link	pending
auph-20221231_g5.jpg	Edgar Link	pending
auph-20221231_g6.jpg	Edgar Link	pending
exhibit1021formofrestricte.htm	Edgar Link	pending
exhibit10ormofinducementre.htm	Edgar Link	pending
exhibit211listofsubsidiari.htm	Edgar Link	pending
exhibit231consentofindepen.htm	Edgar Link	pending
exhibit311certification302.htm	Edgar Link	pending
exhibit312certification302.htm	Edgar Link	pending
exhibit321certificationsox.htm	Edgar Link	pending
exhibit322certificationsox.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
auph-20221231_def.xml	Edgar Link	unprocessable
auph-20221231_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

2023 Q1 Form 10-K Financial Statement

#000162828023005341 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH Aurinia Pharmaceuticals Inc. Stock $auph

2023 Q1 Form 10-K Financial Statement

#000162828023005341 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph